Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

| More on:
A man with a wide, eager smile on his face holds up three fingers.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

S&P/ASX 200 Index (ASX: XJO) healthcare share Sigma Healthcare Ltd (ASX: SIG) is getting caught up in the broader, Trump tariff-fuelled market sell-down today.

Shares in Sigma – which owns Amcal, Discount Drug Stores, Guardian Pharmacy, and, as of February, Chemist Warehouse – closed Friday trading for $2.89. In afternoon trade on Monday, shares are changing hands for $2.74 apiece, down 5.2%.

For some context, the ASX 200 is down 3.8% at this same time.

At the current price, the ASX 200 healthcare share commands a market cap of $31.6 billion.

Despite today's retrace, Sigma shares remain up 125% since this time last year, smashing the benchmark index's 12-month 5.3% losses.

While those juicy gains have come and gone, Sanlam Private Wealth's Remo Greco believes Sigma can continue to outperform over the long term (courtesy of The Bull).

Here's why.

ASX 200 healthcare share on the growth path

"Sigma's merge with Chemist Warehouse Group has created a leading healthcare wholesaler, distributor and retail pharmacy franchisor," said Greco, who has a buy recommendation on the ASX 200 healthcare share.

"Its recent market capitalisation puts the stock in the top 50 on the ASX," he said.

One of the reasons Greco is bullish on Sigma shares relates to Australia's demographics.

"The business benefits from its exposure to Australia's ageing population," he said.

Another reason is Sigma's ongoing store expansions.

"The company will open around 40 new stores a year," Greco said. "We expect the company to generate more revenue and profits from selling products off the shelves than dispensing prescriptions."

The third reason to buy the ASX 200 healthcare share today is the company's strong earnings growth.

According to Greco:

As a stand-alone business, Sigma reported 2025 normalised earnings before interest and tax of $68 million, up 183.5% on the prior corresponding period and at the upper end of the guidance range previously provided.

With Sigma's merger with Chemist Warehouse now a done deal, Greco said, "The merger with Chemist Warehouse Group became effective on February 12, 2025. The stock isn't cheap but worthy of accumulating a position for the longer term."

What's been happening with Sigma shares?

The ASX 200 healthcare share reported its full-year results for the 12 months ending 31 January on 20 March. Those results did not include its newly completed merger with Chemist Warehouse.

In addition to the huge earnings boost Greco mentioned, Sigma's FY 2025 net revenue increased by 50.9% year on year to $4.8 billion. Underlying net profit after tax was up 878% to $41.9 million.

Looking at what's next for the ASX 200 healthcare share, CEO Vikesh Ramsunder said on the day:

Looking ahead and having concluded the merger, our management teams are focused on seamless integration and delivering long term value to shareholders.

We have created a leading wholesaler and retail franchisor with strong growth potential in Australia and progressively internationally.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »